<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946671</url>
  </required_header>
  <id_info>
    <org_study_id>KW0761-IIT-02</org_study_id>
    <nct_id>NCT02946671</nct_id>
  </id_info>
  <brief_title>Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients</brief_title>
  <official_title>Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Study Support, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fiverings Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <brief_summary>
    <textblock>
      To assess the safety of preoperative combination therapy with KW-0761 (anti-CCR4) and
      ONO-4538 (anti-PD-1).

      To assess the behavior of immune cells in peripheral blood and tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events including intraoperative and postoperative complications</measure>
    <time_frame>from first administration to 60 days after the final administration or to 30 days after the standard operation</time_frame>
    <description>Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Foxp3-positive patients in tumor by immunohistochemical analysis</measure>
    <time_frame>from baseline until standard operation, an average of 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate according to RECIST v1.1</measure>
    <time_frame>from baseline to 6 weeks after the first administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Treg decrease in peripheral blood mononuclear cell (PBMC)</measure>
    <time_frame>from baseline to 60 days after the final administration or to 30 days after the standard operation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mogamulizumab</intervention_name>
    <description>Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>KW-0761</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (3.0 mg/kg) is administered.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>ONO-4538</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who enable to have standard operation

          -  Patients who refuse standard preoperative chemotherapy and are diagnosed with
             following cancers; gastric adenocarcinoma, esophageal squamous cell carcinoma,
             non-small-cell lung carcinoma or renal cell carcinoma

          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Patients with no serious disorder of major organs (born marrow, heart, lung, liver and
             kidney)

          -  Patients with written informed consent

          -  Patients who have measurable target lesion

          -  Patients who are enable to undergo biopsy for sampling tumor tissue

        Exclusion Criteria:

          -  Known or previous autoimmune disease

          -  Known or suspected interstitial lung disease (ILD)

          -  Patients with history of serious anaphylaxis induced by antibody preparation

          -  Uncontrollable hypertension

          -  Uncontrollable endocrine disease

          -  Patients who have active inflammatory bowel disease or other serious GI chronic
             conditions associated with diarrhea

          -  Uncontrollable diabetes

          -  Prior therapy with sustained anticancer agents, radiotherapy or surgery for primary
             disease

          -  Pregnant or lactating females, female and male patients who cannot agree to practice
             the adequate birth control after the consent during the study

          -  Known or suspected infection or inflammatory disease

          -  Prior therapy with hematopoietic stem cell transplantation

          -  Known or suspected central nervous system (CNS) involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisashi Wada, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatsushi Goto, Ph.D.</last_name>
    <phone>+81-6-6358-7004</phone>
    <email>gotou@fiverings.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5650871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisashi Wada</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Hisashi Wada</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

